Answers are grounded in this paper and cite their sources.
Background: Systemic lupus erythematosus is an autoimmune disease, with lupus nephritis (LN) as its most serious complication, potentially leading to renal failure. Current treatments, primarily glucocorticoids and immunosuppressive agents, yield complete responses in only 20% to 30% of LN patients, with many experiencing refractory cases. Even those in clinical remission often show active kidney disease based on biopsy results. Owning to the complexity of refractory LN, no standardized treatment exists. Mesenchymal stem cells (MSCs) have immunomodulatory and anti-inflammatory effects and, effectively slow LN progression with few adverse effects. Although MSCs have been tested in 3 registered clinical trials, no endpoint results have been published. These trials face 2 major issues: poorly defined inclusion criteria and not considering the diversity of first-line agents before enrollment. The outcome indicator only focuses on blood and urine tests rather than renal pathology. Considering the powerful therapeutic potential of MSCs, we propose a more rigorous randomized controlled trial to evaluate their efficacy and safety in treating refractory LN. Methods: Ninety-six patients with refractory LN will participate in a patient-blinded, randomized, placebo-controlled trial. Participants will receive either 1 × 106 cells/kg of MSCs or placebo (normal saline) at baseline and 6 months. The primary outcome will be the renal response rate, including complete and partial response rates at 6 and 12 months post-infusion. A renal biopsy will be performed to assess the histological response if a complete response is achieved. Discussion: Most patients with systemic lupus erythematosus develop LN within 5 years, leading to significant morbidity and mortality. Although some treatments are effective, approximately one-third of patients with LN face treatment failure, and medication intolerance is common. This trial will evaluate MSCs as an alternative therapy for refractory LN, with the findings guiding their use in these patients.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: